Date: 2015-12-01
Type of information: Nomination
Compound:
Company: Biophytis (France)
Therapeutic area: Metabolic diseases - Neurodegenerative diseases - Ophtalmological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On December 1, 2015, Biophytis announced that it appoints Pierre J. Dilda, PhD, Director of Research. French-Australian, Dr Dilda has more than 20 years of experience in pharmaceutical research, in both academic and industrial settings. Since 2002, he was Senior Research Fellow at the Lowy Cancer Research Center at the University of New South Wales (UNSW) in Sydney, Australia, where he was responsible for advancing several cancer therapeutics into advanced clinical development. Previously, he held several positions of responsibility for research and development at Mayoly Spindler Laboratories, a French pharmaceutical company. He received his PhD in Pharmacology from University Paris V and is an author on more than 50 peer reviewed publications.
At Biophytis Dr Dilda will be in charge of preclinical development for drug candidates emanating from the company’s discovery platform, including the lead drug-candidates targeting sarcopenic obesity (i.e. Sarcob: BIO101 and BIO103) and dry age related macular degeneration (AMD) (i.e. Maculia: BIO201 and BIO203). In addition, Dr. Dilda will oversee the continued utilization of the discovery platform as well as collaborations with academic and, potentially, future industrial partners. In addition, Dr Dilda will take responsibility for the companies growing intellectual property portfolio, which protects Sarcob, Macula, future molecules and related
technologies.
Financial terms:
Latest news:
